COMMUNIQUÉS West-GlobeNewswire

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer
25/10/2026
Complete responses were seen in 14% of patients with head and neck squamous cell carcinoma (HNSCC) other than human papillomavirus ( HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC); 65% of responses in [...]
Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
25/10/2026
Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline NANJING, China, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Nanjing [...]
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
25/10/2026
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo [...]
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
25/10/2026
MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
25/10/2026
Media Release COPENHAGEN, Denmark; October 25, 2026 Petosemtamab demonstrates encouraging objective response rates (ORRs), with promising depth and durability of response, in first- and second-line metastatic colorectal [...]
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
25/10/2026
Nearly 18 months of median follow-up, selection of the 8 mg/kg dose and FDA engagement strengthen the foundation for registrational development in first-line metastatic gastroesophageal adenocarcinoma Updated Phase 1b [...]
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
25/10/2026
44.8% ORR at 6mg/kg dose in late-line CRC patients ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN [...]
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
25/10/2026
Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression [...]
KFSH Expands Virtual Care Pathways to Bring Specialized Follow-Up Closer to Patients
25/10/2026
RIYADH, Saudi Arabia, Oct. 25, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is expanding virtual and alternative care pathways at its Jeddah hospital, giving patients greater [...]
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
25/10/2026
Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placebo arm upon [...]
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
25/10/2026
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anticipated in 2027 200 [...]
Melbourne coach Dominik Kulewski's Weight Loss Lab clients have now lost about 3 tonnes combined
24/10/2026
Results include a US client who lost 145kg without surgery and a man who lost more than 80kg after being called a lost cause Melbourne, Australia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Clients of Dominik Kulewski, the [...]
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
24/10/2026
Media Release COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal [...]
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
24/10/2026
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety [...]
XBiotech annonce la nomination de Sushma Shivaswamy et Jan-Paul Simard aux postes de co-directeurs généraux
24/10/2026
AUSTIN, Texas, 24 oct. 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd’hui que son conseil d’administration avait élu Jan-Paul Simard au poste de co-directeur général, aux côtés de la directrice [...]
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
24/10/2026
Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmark Disease control rate of 100% across all response-evaluable patients receiving a starting dose [...]
Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress
24/10/2026
Presented first-in-class clinical proof-of-concept data in KRAS G12D mutant CRC with combination of QTX3034 and anti-EGFR ± chemotherapy Combinations demonstrated robust anti-tumor activity with no new safety signals in [...]
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer
24/10/2026
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus hormone therapy compared with immediate surgery 1 Twice as many patients remained free from [...]
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
24/10/2026
Median PFS was 21.5 months with the gedatolisib triplet and 11.5 months with the gedatolisib doublet versus 9.1 months with alpelisib + fulvestrant in patients who had no liver metastases ORR and median duration of [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum